A framework for tailoring clinical guidelines to comorbidity at the point of care.

BACKGROUND Evidence is accumulating to suggest that clinical guidelines should be modified for patients with comorbidities, yet there is no quantitative and objective approach that considers benefits together with risks. METHODS We outline a framework using a payoff time, which we define as the minimum elapsed time until the cumulative incremental benefits of a guideline exceed its cumulative incremental harms. If the payoff time of a guideline exceeds a patient's comorbidity-adjusted life expectancy, then the guideline is unlikely to offer a benefit and should be modified. We illustrate the framework by applying this method to colorectal cancer screening guidelines for 50-year-old men with human immunodeficiency virus (HIV) and 60-year-old women with congestive heart failure (CHF). RESULTS We estimated that colorectal cancer screening payoff times for 50-year-old men with HIV would range from 1.9 to 5.0 years and that colorectal cancer screening payoff times for 60-year-old women with CHF would range from 0.7 to 2.9 years. Because the payoff times for 50-year-old men with HIV were lower than their life expectancies (12.5-24.0 years), colorectal cancer screening may be beneficial for these patients. In contrast, because payoff times for 60-year-old women with CHF were sometimes greater than their life expectancies (0.6 to >5 years), colorectal cancer screening is likely to be harmful for some of these patients. CONCLUSION Use of a payoff time calculation may be a feasible framework to tailor clinical guidelines to the comorbidity profiles of individual patients.

[1]  M. Tinetti,et al.  The Effect of Age and Chronic Illness on Life Expectancy after a Diagnosis of Colorectal Cancer: Implications for Screening , 2006, Annals of Internal Medicine.

[2]  J. Mitchell,et al.  A DECISION MODEL AND COST-EFFECTIVENESS ANALYSIS OF COLORECTAL CANCER SCREENING AND SURVEILLANCE GUIDELINES FOR AVERAGE-RISK ADULTS , 2000, International Journal of Technology Assessment in Health Care.

[3]  Michael Pignone,et al.  Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. , 2002, Annals of internal medicine.

[4]  Mark S Roberts,et al.  Estimating the rate of accumulating drug resistance mutations in the HIV genome. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  Mark S Roberts,et al.  Estimating the proportion of patients infected with HIV who will die of comorbid diseases. , 2005, The American journal of medicine.

[6]  Steven M. Shechter,et al.  Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. , 2006, The Journal of antimicrobial chemotherapy.

[7]  J. Wike,et al.  The Influence of Year-End Bonuses on Colorectal Cancer Screening , 2003, The American journal of managed care.

[8]  J R Beck,et al.  A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. , 1982, The American journal of medicine.

[9]  R. Hayward,et al.  Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. , 2001, The American journal of medicine.

[10]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[11]  J D Habbema,et al.  Endoscopic colorectal cancer screening: a cost-saving analysis. , 2000, Journal of the National Cancer Institute.

[12]  G. Alexander,et al.  Reconsidering medication appropriateness for patients late in life. , 2006, Archives of internal medicine.

[13]  Karla Lindquist,et al.  Development and validation of a prognostic index for 4-year mortality in older adults. , 2006, JAMA.

[14]  Robert W. Klein,et al.  Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages , 2000 .

[15]  L. Walter,et al.  Cancer screening in elderly patients: a framework for individualized decision making. , 2001, JAMA.

[16]  S. Durso,et al.  Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. , 2006, JAMA.

[17]  Hermann Brenner,et al.  Cost-effectiveness of colonoscopy in screening for colorectal cancer. , 2002, Archives of internal medicine.

[18]  Graham A. Colditz,et al.  Cost-effectiveness of screening for colorectal cancer in the general population. , 2000, JAMA.

[19]  M. Tinetti,et al.  Potential pitfalls of disease-specific guidelines for patients with multiple conditions. , 2004, The New England journal of medicine.

[20]  A. Wu,et al.  Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. , 2005, JAMA.